- Home
- TLSI vs EOD Comparison
TLSI vs EOD Comparison
Compare TLSI & EOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- EOD
- Stock Information
- Founded
- TLSI 2010
- EOD 2007
- Country
- TLSI United States
- EOD United States
- Employees
- TLSI N/A
- EOD N/A
- Industry
- TLSI Medical Specialities
- EOD Investment Managers
- Sector
- TLSI Health Care
- EOD Finance
- Exchange
- TLSI Nasdaq
- EOD Nasdaq
- Market Cap
- TLSI 204.0M
- EOD 213.8M
- IPO Year
- TLSI N/A
- EOD N/A
- Fundamental
- Price
- TLSI $5.54
- EOD $5.16
- Analyst Decision
- TLSI Strong Buy
- EOD
- Analyst Count
- TLSI 5
- EOD 0
- Target Price
- TLSI $10.90
- EOD N/A
- AVG Volume (30 Days)
- TLSI 39.7K
- EOD 118.1K
- Earning Date
- TLSI 08-13-2025
- EOD 01-01-0001
- Dividend Yield
- TLSI N/A
- EOD 9.28%
- EPS Growth
- TLSI N/A
- EOD N/A
- EPS
- TLSI N/A
- EOD N/A
- Revenue
- TLSI $32,141,000.00
- EOD N/A
- Revenue This Year
- TLSI $55.52
- EOD N/A
- Revenue Next Year
- TLSI $54.76
- EOD N/A
- P/E Ratio
- TLSI N/A
- EOD N/A
- Revenue Growth
- TLSI 46.20
- EOD N/A
- 52 Week Low
- TLSI $3.50
- EOD $3.73
- 52 Week High
- TLSI $6.08
- EOD $4.71
- Technical
- Relative Strength Index (RSI)
- TLSI 53.07
- EOD 49.86
- Support Level
- TLSI $5.18
- EOD $5.18
- Resistance Level
- TLSI $5.54
- EOD $5.26
- Average True Range (ATR)
- TLSI 0.32
- EOD 0.05
- MACD
- TLSI 0.01
- EOD -0.02
- Stochastic Oscillator
- TLSI 82.81
- EOD 21.74
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.